Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Gains from Sales and Divestitures (2016 - 2025)

Collegium Pharmaceutical has reported Gains from Sales and Divestitures over the past 11 years, most recently at $980992.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 90.84% year-over-year to $980992.0; the TTM value through Sep 2025 reached $980992.0, up 90.84%, while the annual FY2024 figure was $967773.0, 333.65% up from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $980992.0 at Collegium Pharmaceutical, up from $895705.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $980992.0 in Q3 2025 and troughed at $66974.0 in Q2 2021.
  • A 5-year average of $507047.5 and a median of $514050.0 in 2024 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 75.97% in 2021 and later skyrocketed 718.27% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $444769.0 in 2021, then increased by 28.88% to $573204.0 in 2022, then plummeted by 61.07% to $223170.0 in 2023, then surged by 333.65% to $967773.0 in 2024, then rose by 1.37% to $980992.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for COLL at $980992.0 in Q3 2025, $895705.0 in Q2 2025, and $792945.0 in Q1 2025.